Liquidia CORP 8-K filings

Liquidia Corporation has successfully raised approximately $100 million through a public offering, private placement, and an amendment to its existing royalty financing agreement, to support the commercial development of YUTREPIA and other clinical programs.

Liquidia Corporation has secured the remaining $32.5 million under its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, modifying the payment schedule and extending the payment term.

Liquidia Corporation has filed a lawsuit against the FDA challenging the grant of exclusivity to Tyvaso DPI, which is delaying the final approval of their drug YUTREPIA.

Liquidia's YUTREPIA receives tentative FDA approval for PAH and PH-ILD, but final approval is delayed due to a competitor's regulatory exclusivity.

Liquidia Corporation reported its second quarter 2024 financial results, highlighting progress in its legal battles and clinical programs, while also noting a decrease in revenue and an increase in operating expenses.

Liquidia Corporation successfully held its annual meeting, electing directors, increasing authorized shares, and ratifying the appointment of its accounting firm.

Liquidia Corporation secured a favorable court decision denying a preliminary injunction that sought to block the launch of their YUTREPIA drug for pulmonary hypertension associated with interstitial lung disease.

Liquidia Corporation is being sued by United Therapeutics for alleged intellectual property misappropriation related to its product candidate YUTREPIA.

Liquidia Corporation has updated its executive severance plan, outlining benefits for key employees upon involuntary termination, both within and outside of a change in control period.

Liquidia Corporation announced its first quarter 2024 financial results, highlighting progress in legal battles and clinical trials for its drug YUTREPIA, alongside a significant increase in operating expenses.

Liquidia Corporation has overcome key legal challenges, paving the way for potential FDA approval of its YUTREPIA inhalation powder for pulmonary hypertension.

Liquidia Corporation announced its full year 2023 financial results and provided a corporate update, highlighting preparations for the launch of YUTREPIA and advancements in its inhaled treprostinil portfolio.

Liquidia Corporation has received an update from the FDA regarding the review of its New Drug Application for YUTREPIA, with the FDA confirming the process for adding the PH-ILD indication as an amendment.

Liquidia Corporation has had claims related to one patent dismissed in an ongoing patent infringement lawsuit with United Therapeutics, while awaiting a court decision on a separate injunction.

Liquidia Corporation has promoted its CFO, Michael Kaseta, to the dual role of Chief Operating Officer and CFO, effective January 15, 2024, while the former COO transitions out of the company.